Cargando…

Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer

Recent studies unraveled that AT-rich interactive domain-containing protein 1A (ARID1A), a subunit of the mammary SWI/SNF chromatin remodeling complex, acts as a tumor suppressor in various cancers. In this study, we first evaluated ARID1A expression by immunohistochemistry in invasive breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Takao, Chika, Morikawa, Akemi, Ohkubo, Hiroshi, Kito, Yusuke, Saigo, Chiemi, Sakuratani, Takuji, Futamura, Manabu, Takeuchi, Tamotsu, Yoshida, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264034/
https://www.ncbi.nlm.nih.gov/pubmed/28123592
http://dx.doi.org/10.7150/jca.16602
_version_ 1782500024220909568
author Takao, Chika
Morikawa, Akemi
Ohkubo, Hiroshi
Kito, Yusuke
Saigo, Chiemi
Sakuratani, Takuji
Futamura, Manabu
Takeuchi, Tamotsu
Yoshida, Kazuhiro
author_facet Takao, Chika
Morikawa, Akemi
Ohkubo, Hiroshi
Kito, Yusuke
Saigo, Chiemi
Sakuratani, Takuji
Futamura, Manabu
Takeuchi, Tamotsu
Yoshida, Kazuhiro
author_sort Takao, Chika
collection PubMed
description Recent studies unraveled that AT-rich interactive domain-containing protein 1A (ARID1A), a subunit of the mammary SWI/SNF chromatin remodeling complex, acts as a tumor suppressor in various cancers. In this study, we first evaluated ARID1A expression by immunohistochemistry in invasive breast cancer tissue specimens and assessed the correlation with the prognosis of patients with breast cancer. Non-tumorous mammary duct epithelial cells exhibited strong nuclear ARID1A staining, whereas different degrees of loss in ARID1A immunoreactivity were observed in many invasive breast cancer cells. We scored ARID1A immunoreactivity based on the sum of the percentage score in invasive cancer cells (on a scale of 0 to 5) and the intensity score (on a scale of 0 to 3), for a possible total score of 0 to 8. Interestingly, partial loss of ARID1A expression, score 2 to 3, was significantly correlated with poor disease free survival of the patients. Subsequently, we performed siRNA-mediated ARID1A knockdown in cultured breast cancer cells followed by comprehensive gene profiling and quantitative RT-PCR. Interestingly, many genes were downregulated by partial loss of ARID1A, whereas RAB11FIP1 gene expression was significantly upregulated by partial loss of ARID1A expression in breast cancer cells. In contrast, a more than 50% reduction in ARID1A mRNA decreased RAB11FIP1gene expression. Immunoblotting also demonstrated that partial downregulation of ARID1A mRNA at approximately 20% reduction significantly increased the expression of RAB11FIP1 protein in MCF-7 cells, whereas, over 50% reduction of ARID1A mRNA resulted in reduction of RAB11FIP1 protein in cultured breast cancer cells. Recent studies reveal that RAB11FIP1 overexpression leads to breast cancer progression. Altogether, the present findings indicated that partial loss of ARID1A expression is linked to unfavorable outcome for patients with breast cancer, possibly due to increased RAB11FIP1 expression.
format Online
Article
Text
id pubmed-5264034
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-52640342017-01-25 Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer Takao, Chika Morikawa, Akemi Ohkubo, Hiroshi Kito, Yusuke Saigo, Chiemi Sakuratani, Takuji Futamura, Manabu Takeuchi, Tamotsu Yoshida, Kazuhiro J Cancer Research Paper Recent studies unraveled that AT-rich interactive domain-containing protein 1A (ARID1A), a subunit of the mammary SWI/SNF chromatin remodeling complex, acts as a tumor suppressor in various cancers. In this study, we first evaluated ARID1A expression by immunohistochemistry in invasive breast cancer tissue specimens and assessed the correlation with the prognosis of patients with breast cancer. Non-tumorous mammary duct epithelial cells exhibited strong nuclear ARID1A staining, whereas different degrees of loss in ARID1A immunoreactivity were observed in many invasive breast cancer cells. We scored ARID1A immunoreactivity based on the sum of the percentage score in invasive cancer cells (on a scale of 0 to 5) and the intensity score (on a scale of 0 to 3), for a possible total score of 0 to 8. Interestingly, partial loss of ARID1A expression, score 2 to 3, was significantly correlated with poor disease free survival of the patients. Subsequently, we performed siRNA-mediated ARID1A knockdown in cultured breast cancer cells followed by comprehensive gene profiling and quantitative RT-PCR. Interestingly, many genes were downregulated by partial loss of ARID1A, whereas RAB11FIP1 gene expression was significantly upregulated by partial loss of ARID1A expression in breast cancer cells. In contrast, a more than 50% reduction in ARID1A mRNA decreased RAB11FIP1gene expression. Immunoblotting also demonstrated that partial downregulation of ARID1A mRNA at approximately 20% reduction significantly increased the expression of RAB11FIP1 protein in MCF-7 cells, whereas, over 50% reduction of ARID1A mRNA resulted in reduction of RAB11FIP1 protein in cultured breast cancer cells. Recent studies reveal that RAB11FIP1 overexpression leads to breast cancer progression. Altogether, the present findings indicated that partial loss of ARID1A expression is linked to unfavorable outcome for patients with breast cancer, possibly due to increased RAB11FIP1 expression. Ivyspring International Publisher 2017-01-01 /pmc/articles/PMC5264034/ /pubmed/28123592 http://dx.doi.org/10.7150/jca.16602 Text en © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Takao, Chika
Morikawa, Akemi
Ohkubo, Hiroshi
Kito, Yusuke
Saigo, Chiemi
Sakuratani, Takuji
Futamura, Manabu
Takeuchi, Tamotsu
Yoshida, Kazuhiro
Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer
title Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer
title_full Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer
title_fullStr Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer
title_full_unstemmed Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer
title_short Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer
title_sort downregulation of arid1a, a component of the swi/snf chromatin remodeling complex, in breast cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264034/
https://www.ncbi.nlm.nih.gov/pubmed/28123592
http://dx.doi.org/10.7150/jca.16602
work_keys_str_mv AT takaochika downregulationofarid1aacomponentoftheswisnfchromatinremodelingcomplexinbreastcancer
AT morikawaakemi downregulationofarid1aacomponentoftheswisnfchromatinremodelingcomplexinbreastcancer
AT ohkubohiroshi downregulationofarid1aacomponentoftheswisnfchromatinremodelingcomplexinbreastcancer
AT kitoyusuke downregulationofarid1aacomponentoftheswisnfchromatinremodelingcomplexinbreastcancer
AT saigochiemi downregulationofarid1aacomponentoftheswisnfchromatinremodelingcomplexinbreastcancer
AT sakuratanitakuji downregulationofarid1aacomponentoftheswisnfchromatinremodelingcomplexinbreastcancer
AT futamuramanabu downregulationofarid1aacomponentoftheswisnfchromatinremodelingcomplexinbreastcancer
AT takeuchitamotsu downregulationofarid1aacomponentoftheswisnfchromatinremodelingcomplexinbreastcancer
AT yoshidakazuhiro downregulationofarid1aacomponentoftheswisnfchromatinremodelingcomplexinbreastcancer